5 Behandling med nukleosidanaloger bør stoppes i tilfælde af symptomatisk hyperlactatæmi og metabolisk acidose/ lactacidose, fremadskridende hepatomegali eller hurtigt stigende aminotransferaseniveauer.
5 Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.